Principal Financial Group Inc. Purchases 4,669 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Principal Financial Group Inc. boosted its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 2.2% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 212,647 shares of the company’s stock after purchasing an additional 4,669 shares during the quarter. Principal Financial Group Inc. owned about 0.45% of Amphastar Pharmaceuticals worth $6,165,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth $38,000. GAMMA Investing LLC grew its position in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock worth $39,000 after purchasing an additional 424 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Amphastar Pharmaceuticals by 43.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock worth $43,000 after purchasing an additional 348 shares during the period. Huntington National Bank raised its position in shares of Amphastar Pharmaceuticals by 36.9% in the fourth quarter. Huntington National Bank now owns 1,340 shares of the company’s stock valued at $50,000 after buying an additional 361 shares in the last quarter. Finally, TD Private Client Wealth LLC raised its position in shares of Amphastar Pharmaceuticals by 22.7% in the fourth quarter. TD Private Client Wealth LLC now owns 2,099 shares of the company’s stock valued at $78,000 after buying an additional 388 shares in the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently weighed in on AMPH. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $30.00 target price (down from $45.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 12th. Wells Fargo & Company decreased their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a research note on Thursday, May 8th. Piper Sandler cut their target price on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research note on Friday, March 21st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $32.33.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH stock opened at $21.27 on Thursday. The business’s 50-day moving average price is $24.35 and its 200-day moving average price is $28.01. Amphastar Pharmaceuticals, Inc. has a 12 month low of $21.09 and a 12 month high of $53.96. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80. The firm has a market capitalization of $1.00 billion, a price-to-earnings ratio of 7.71, a PEG ratio of 5.52 and a beta of 0.72.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.